ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada's Drug Agency for Gastric Cancer Français

MISSISSAUGA, ON, May 23, 2025 /CNW/ - AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric cancer – for ENHERTU ® (trastuzumab deruxtecan) based on the unmet need of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Additionally, the pan-Canadian Pharmaceutical Alliance (pCPA), AstraZeneca, and Daiichi Sankyo have recently signed a Letter of Intent (LOI) through the recently introduced Temporary Access Process (pTAP). This step, alongside the CDA TLR processes, paves the way for jurisdictional reimbursement.
"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients, particularly in areas of great unmet need, such as HER2+ gastric cancer," says Gaby Bourbara, President, AstraZeneca Canada. "The TLR/pTAP process is intended for a subset of medicines assessed with a very specific set of criteria, and we look forward to continuing to work with our partners within the drug reimbursement ecosystem to unlock additional mechanisms for accelerating access to more medicines in the future."
It is estimated that these processes will make ENHERTU available to gastric cancer patients close to two years faster than traditional reimbursement pathways which would have required the completion and review of the Phase III DESTINY-Gastric04 study.
"Daiichi Sankyo and our partners at AstraZeneca are committed to ongoing collaboration with the HTA bodies to identify and leverage new ways to make medicines accessible to patients across the country as fast as possible following Health Canada approval," says Fatih Yedikardeş, Country Manager, Daiichi Sankyo Canada.
For medications that show early promise and have been given conditional regulatory approval, the TLR and pTAP processes represent a path for accelerated access while ongoing confirmatory trials are in progress. 1,2
Health Canada granted a Notice of Compliance with conditions (NOC/c) for ENHERTU (trastuzumab deruxtecan) on January 17, 2025, for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. 3 The conditional approval was authorized based on results from DESTINY-Gastric02 4 and DESTINY-Gastric01 5 Phase II trials. The confirmatory Phase III trial, DESTINY-Gastric04 6 is currently underway and is a global, randomized, open-label, trial evaluating the efficacy and safety of trastuzumab deruxtecan (6.4 mg/kg) versus ramucirumab and paclitaxel in patients with HER2- positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.
About Gastric Cancer
Gastric (stomach) cancer is the fifth most common cancer worldwide and the fourth leading cause of cancer mortality with a five-year survival rate of 7.5% for metastatic disease. 7,8 In Canada, it is estimated that 4,200 people will be diagnosed, and 2,000 people will die from the disease this year. 9
About ENHERTU
ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.
About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo Company, Limited (referred to as Daiichi Sankyo) and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in March 2019 and datopotamab deruxtecan (Dato-DXd) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and datopotamab deruxtecan.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer.
AstraZeneca is committed to contributing to a more sustainable future for people, society and planet, taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at www.astrazeneca.ca.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society." For more information, please visit http://www.daiichi-sankyo.eu.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Cision Canada

16-06-2025

• Cision Canada

VANFLYTA® is Now Approved in Canada Specifically for Adult Patients with Newly Diagnosed FLT3-ITD Positive AML Français

After ENHERTU ®, VANFLYTA ® is the second innovative medicine from the Daiichi Sankyo oncology pipeline to be available in Canada Approval based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival TORONTO, June 16, 2025 /CNW/ - Daiichi Sankyo's (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3-internal tandem duplication (FLT3 -ITD) positive. 1 Improvement in overall survival (OS) has not been demonstrated for maintenance monotherapy following allogeneic hematopoietic stem cell transplantation. 1 A validated test is required to confirm the FLT3 -ITD status of AML. 1 AML is one of the most common forms of leukemia in adults, representing approximately 80% of all cases. 2 FLT3 gene mutations occur in approximately 30% of newly diagnosed patients with AML. 3 Approximately 80% of these are FLT3 -ITD mutations, which drive cancer growth and contribute to an increased risk of relapse and shorter overall survival. 3,4 FLT3 -ITD mutations occur in roughly 25% of all AML cases, with some studies reporting a frequency as high as 30%. 3,4 The five-year survival rate for Canadian patients with AML receiving the current standard of care has been reported at approximately 23%. 5 VANFLYTA is a novel selective FLT3 -ITD inhibitor that when used in combination with standard chemotherapy and across all three phases of treatment: induction, consolidation and maintenance, provides proven survival outcomes in newly diagnosed FLT3 -ITD positive AML - even in a population of adults up to 75 years of age. 6 The approval of VANFLYTA by Health Canada was based on the results of the QuANTUM-First phase 3 clinical trial. In QuANTUM-First, VANFLYTA combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation and continued as maintenance monotherapy following consolidation, demonstrated a 22.4% reduction in the risk of death compared to standard chemotherapy alone (HR = 0.78 [95% CI: 0.62-0.98; 2-sided p=0.0324]) in patients with newly diagnosed FLT3 -ITD positive AML. 1,6 Median OS was 31.9 months for patients receiving VANFLYTA (n=268; 95% CI: 21.0-NE) compared to 15.1 months for patients in the control arm (n=271; 95% CI: 13.2-26.2) at a median follow-up of 39.2 months. 6 "The approval of VANFLYTA in Canada represents a significant advancement for the treatment of patients with newly diagnosed FLT3 -ITD positive AML, which is one of the most aggressive and difficult-to-treat subtypes," said Brian Leber, MD, FRCP, Professor of Medicine, Department of Medicine, McMaster University. "In the QuANTUM-First trial, VANFLYTA added to standard chemotherapy and continued as maintenance resulted in longer remission and prolonged overall survival and it will be a much needed new treatment option that has potential to change the way FLT3 -ITD positive AML is treated." QuANTUM-First evaluated the safety profile in 265 patients with newly diagnosed FLT3 -ITD positive AML treated with VANFLYTA. The most common grade 3 or 4 adverse reactions (incidence ≥ 5%) were febrile neutropenia, sepsis, neutropenia, thrombocytopenia, fungal infections and anemia. 1,6 Cardiac events, such as QT prolongation and rare ventricular arrhythmias, also were observed. 6 "Despite recent advances in AML treatment, patients with AML bearing FLT3 -ITD mutations still face a challenging prognosis," said Andre Schuh, MD, FRCPC, Clinician Investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre. "The approval of VANFLYTA offers a promising step forward, bringing hope for better outcomes in this high-risk patient population. Results from the QuANTUM-First trial demonstrated that combining VANFLYTA with standard chemotherapy and continuing it as maintenance therapy, led to deeper, more durable remissions and improved overall survival. As a new option for newly diagnosed FLT3 -ITD positive AML, VANFLYTA has the potential to redefine how this aggressive disease is treated in Canada." "The approval of VANFLYTA in Canada enables patients diagnosed with FLT3 -ITD-positive acute myeloid leukemia to receive a targeted therapy specifically developed for their disease subtype," said Fatih Yedikardeş, Country Manager Canada, Daiichi Sankyo. "This milestone reflects our commitment to transforming cancer therapy, advancing innovation in hematology and oncology and creating new standards of care for patients." About QuANTUM-First QuANTUM-First is a randomized, double-blind, placebo-controlled, global phase 3 study evaluating VANFLYTA versus standard chemotherapy on overall survival in adult patients aged 20-75 with newly diagnosed FLT3 -ITD positive AML. The primary endpoint of the study was OS. Secondary endpoints included event-free survival, post-induction rate of complete remission (CR), composite complete remission (CRc) and the percentage of patients who achieve CR or CRc with FLT3 -ITD measurable residual disease negativity. Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints, including duration of CR, also were evaluated. 6 QuANTUM-First enrolled 539 patients at 193 study sites across Asia, Europe, North America, Oceania and South America. For more information, visit About FLT3 -ITD Positive Acute Myeloid Leukemia Approximately 487,000 new cases of leukemia were diagnosed globally in 2022, leading to more than 305,000 deaths. 7 AML accounts for approximately 23% of total leukemia cases worldwide. 8 The disease arises from the abnormal proliferation and differentiation of myeloid stem cells in the bone marrow. 2 In Canada, 1,286 people died from AML in 2022 and it remains the second most commonly diagnosed blood cancer in the country. 9,10 About VANFLYTA VANFLYTA is an oral, highly potent and selective type II FLT3 inhibitor approved in more than 30 countries in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherapy following consolidation, for the treatment of adult patients with newly diagnosed AML that is FLT3 -ITD positive based on the results from the QuANTUM-First trial. 1,3 VANFLYTA is an investigational medicine in all countries outside of Canada, Hong Kong, EU, Switzerland, Scotland, United Kingdom, Japan, and the U.S. About the VANFLYTA Clinical Development Program The VANFLYTA clinical development program includes the QuANTUM-Wild phase 3 trial in adult patients with newly diagnosed FLT3 -ITD negative AML, a phase 1/2 trial in pediatric and young adult patients with relapsed/refractory FLT3 -ITD positive AML in Europe, Asia and North America and several phase 1/2 combination studies as part of a strategic collaboration with The University of Texas MD Anderson Cancer Center. About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit References LEGAL: © 2025 Daiichi Sankyo Pharma Canada Ltd. VANFLYTA is a registered trademark of Daiichi Sankyo Co., Ltd., used by Daiichi Sankyo Pharma Canada Ltd. under license.

CTV News

13-06-2025

• CTV News

AstraZeneca signs US$5 billion research deal with China's CSPC

A general view of AstraZeneca offices and the corporate logo in Cambridge, England, on July 18, 2020. (AP Photo/Alastair Grant) AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under the agreement, the two companies will collaborate to discover and develop pre-clinical candidates for potential treatments targeting chronic diseases, with CSPC conducting AI-driven research in Shijiazhuang City. Cambridge, U.K.-based AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion in development milestones and $3.6 billion in sales-related milestones, AstraZeneca said. In March, AstraZeneca announced plans to invest $2.5 billion in a research and development hub in Beijing, as it works to rebuild trust in its second-largest market. Reporting by Pushkala Aripaka in Bengaluru; Editing by Tasim Zahid, Reuters

National Post

11-06-2025

• National Post

The best toothpastes approved by the Canadian Dental Association

When it comes to maintaining a healthy smile, staying on top of your oral hygiene is a must. After all, with the right tools at your disposal you'll be sure to keep your teeth and gums looking their best for years to come. Article content In case you're looking for the products that have the seal of approval from Canadian dentists, you've come to the right place. The Canadian Dental Association (CDA) lists their recommendations for everything from electric toothbrushes to dental floss so you can rest assured that what you're buying actually lives up to its claims. Article content Article content As for toothpaste, there's a huge range of CDA-verified products to choose from depending on the oral health issue that you're looking to target. Keep reading for the best toothpastes to suit your unique needs. Article content Article content Get brighter, whiter-looking teeth with the advanced stain-removal found in this Colgate toothpaste. It whitens and protects against cavities, as well as reduces bacteria on the teeth, tongue, cheeks and gums. Article content Those looking for a more natural toothpaste will be pleased to know that this Burt's Bees option does just as good a job at fighting cavities as other brands. It's formulated without sodium lauryl sulfate (SLS), triclosan, artificial flavours and sweeteners, or dyes – though it does contain fluoride for protection.